Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-27 07:00 |
Biophytis announces its participation to the BIOMED FORUM investor conference
|
English | 161.0 KB | ||
| 2025-01-21 07:00 |
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Di…
|
English | 373.7 KB | ||
| 2025-01-21 07:00 |
Biophytis et AskHelpU signent un accord de co-développement dans les maladies r…
|
French | 386.9 KB | ||
| 2025-01-14 07:00 |
Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company t…
|
English | 199.0 KB | ||
| 2025-01-14 07:00 |
Biophytis entre en négociation exclusive avec une société pharmaceutique chinoi…
|
French | 207.4 KB | ||
| 2025-01-08 07:00 |
Biophytis Announces New Cash Contribution and Debt Conversion up to €8.6 millio…
|
English | 171.3 KB | ||
| 2025-01-08 07:00 |
Biophytis annonce un nouvel apport en cash et une conversion de dettes pouvant …
|
French | 179.7 KB | ||
| 2025-01-06 08:30 |
Biophytis announces temporary suspension of the listing of its shares and share…
|
English | 168.6 KB | ||
| 2025-01-06 08:30 |
Biophytis annonce la suspension temporaire de la cotation de ses actions et de …
|
French | 179.0 KB | ||
| 2024-12-24 07:00 |
Biophytis sera à San Francisco durant la JP Morgan Healthcare Conference de 2025
|
French | 207.2 KB | ||
| 2024-12-24 07:00 |
Biophytis Will Be In San Franscico During The 2025 JP Morgan Healthcare Confere…
|
English | 188.4 KB | ||
| 2024-12-23 07:00 |
Biophytis showcased the OBA program in obesity at the 17th SCWD international c…
|
English | 221.4 KB | ||
| 2024-12-23 07:00 |
Biophytis a présenté le programme OBA dans l'obésité lors du 17ème congrès inte…
|
French | 194.8 KB | ||
| 2024-12-02 07:00 |
Biophytis participates in the 17th SCWD Congress and hosts an Obesity Investor …
|
English | 129.2 KB | ||
| 2024-12-02 07:00 |
Biophytis participe à la 17ème édition du congrès SCWD et organise un Obesity I…
|
French | 152.2 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
